{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:06:32Z","timestamp":1775235992891,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jchromb.2020.122254","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T03:26:56Z","timestamp":1592882816000},"page":"122254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["LC-MS\/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors"],"prefix":"10.1016","volume":"1152","author":[{"given":"Bo","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Campagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Salloum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Purzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2020.122254_b0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","article-title":"Medulloblastoma","volume":"5","author":"Northcott","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jchromb.2020.122254_b0010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1586\/ern.12.66","article-title":"Molecular subgroups of medulloblastoma","volume":"12","author":"Northcott","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jchromb.2020.122254_b0015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/1570159X15666171129111324","article-title":"Childhood medulloblastoma: current therapies, emerging molecular landscape and newer therapeutic insights","volume":"16","author":"Khatua","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jchromb.2020.122254_b0020","doi-asserted-by":"crossref","first-page":"111581","DOI":"10.1016\/j.ejmech.2019.111581","article-title":"Small molecule modulators targeting protein kinase CK1 and CK2","volume":"181","author":"Qiao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jchromb.2020.122254_b0025","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","article-title":"CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy","volume":"70","author":"Siddiqui-Jain","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jchromb.2020.122254_b0030","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3087","article-title":"Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2","volume":"29","author":"Marschke","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jchromb.2020.122254_b0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fphar.2015.00070","article-title":"The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies","volume":"6","author":"Chon","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.122254_b0040","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau5147","article-title":"Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma","volume":"11","author":"Purzner","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jchromb.2020.122254_b0045","unstructured":"Guidance for Industry, Bioanalytical Method Validation, in: F. US Department of Health and Human Services, CDER, CVM (Ed.), May 2018."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023220302671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023220302671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:03:23Z","timestamp":1761606203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023220302671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":9,"alternative-id":["S1570023220302671"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122254","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC-MS\/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122254"}}